[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 525, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 54, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1604037, "exercisedValue": 5264484, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kenneth A. Myszkowski", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 834343, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 59, "title": "COO, General Counsel & Secretary", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 835137, "exercisedValue": 990400, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 45, "title": "Chief of Discovery & Translational Medicine", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 762143, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 69, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 69, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracie  Oliver", "age": 61, "title": "Chief Commercial Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 449579, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 8, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 4, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "maxAge": 86400, "priceHint": 2, "previousClose": 23.98, "open": 24.15, "dayLow": 23.07, "dayHigh": 24.15, "regularMarketPreviousClose": 23.98, "regularMarketOpen": 24.15, "regularMarketDayLow": 23.07, "regularMarketDayHigh": 24.15, "beta": 0.966, "forwardPE": -5.444965, "volume": 674056, "regularMarketVolume": 674056, "averageVolume": 1022387, "averageVolume10days": 840860, "averageDailyVolume10Day": 840860, "bid": 17.4, "ask": 23.28, "bidSize": 200, "askSize": 100, "marketCap": 2890323712, "fiftyTwoWeekLow": 20.67, "fiftyTwoWeekHigh": 39.83, "priceToSalesTrailing12Months": 147.10524, "fiftyDayAverage": 25.8801, "twoHundredDayAverage": 27.5541, "currency": "USD", "enterpriseValue": 3009160192, "floatShares": 110461580, "sharesOutstanding": 124315000, "sharesShort": 10450472, "sharesShortPriorMonth": 9044745, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0841, "heldPercentInsiders": 0.044660002, "heldPercentInstitutions": 0.80559, "shortRatio": 10.08, "shortPercentOfFloat": 0.0986, "impliedSharesOutstanding": 124315000, "bookValue": 2.661, "priceToBook": 8.737317, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -538636032, "trailingEps": -4.65, "forwardEps": -4.27, "pegRatio": -0.7, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 153.154, "enterpriseToEbitda": -5.68, "52WeekChange": -0.20648575, "SandP52WeekChange": 0.24014747, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ARWR", "underlyingSymbol": "ARWR", "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 756052200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c1090240-5c7b-33ae-b362-c474642e552e", "messageBoardId": "finmb_203142", "gmtOffSetMilliseconds": -14400000, "currentPrice": 23.25, "targetHighPrice": 71.0, "targetLowPrice": 20.0, "targetMeanPrice": 47.29, "targetMedianPrice": 50.5, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 14, "totalCash": 434471008, "totalCashPerShare": 3.495, "ebitda": -529777984, "totalDebt": 454124000, "quickRatio": 4.492, "currentRatio": 4.654, "totalRevenue": 19648000, "debtToEquity": 133.97, "revenuePerShare": 0.17, "returnOnAssets": -0.40724, "returnOnEquity": -1.51843, "freeCashflow": -413913760, "operatingCashflow": -351560992, "grossMargins": 1.0, "operatingMargins": -27.85052, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]